Proton Pump Inhibitor Kidney Lawsuits in 2026: the Claims, the Science, and Who Qualifies
PPI kidney lawsuits allege that heartburn drugs such as Nexium, Prilosec, and Prevacid can cause kidney injury, and that makers failed to warn users. In 2026 the litigation is partially settled: AstraZeneca paid $425 million in October 2023 to resolve about 11,000 claims, and roughly 11,400 cases remain pending in the federal MDL.
Proton pump inhibitors are among America's most widely used drugs, sold by prescription and over the counter as Nexium, Prilosec, Prevacid, and Protonix.
What the lawsuits allege
The core claim is failure to warn. Plaintiffs say manufacturers knew, or should have known, that PPIs can trigger acute interstitial nephritis (AIN) — inflammation of the kidney tubules that often arrives without dramatic symptoms — and that repeated episodes can scar the kidneys and progress to chronic kidney disease (CKD), the gradual loss of kidney function, and in severe cases to end-stage renal failure requiring dialysis or transplant.
Each case must prove both general causation (PPIs can cause kidney injury) and specific causation (PPI use caused this person's injury). Courts test the science through Daubert hearings, where a judge rules on whether expert testimony rests on sound methodology. Similar gatekeeping shaped the Zantac cancer lawsuits.
The science behind the claims
Plaintiffs rely on two large 2016 observational studies. Lazarus and colleagues, in JAMA Internal Medicine, followed more than 10,000 people and reported PPI users had roughly a 50 percent higher risk of developing chronic kidney disease than non-users (PMID: 26752337). Xie and colleagues, in the Journal of the American Society of Nephrology, linked PPI use to both incident CKD and progression to end-stage renal disease (PMID: 27080976).
Defendants counter that observational studies show association, not proof — PPI users tend to be older and sicker, which can distort the numbers. The same fight over observational evidence decided other drug litigations, including the Belviq cancer lawsuits. For plain-language video explainers of how mass-tort science is tested, the Problem Solved YouTube channel covers litigation topics step by step.
MDL 2789: where the litigation stands in 2026
The federal cases are centralized as MDL 2789 — In re: Proton-Pump Inhibitor Products Liability Litigation (No. II) — before Judge Claire C. Cecchi in the U.S. District Court for the District of New Jersey, centralized in 2017. Per the Judicial Panel on Multidistrict Litigation, about 11,404 cases were pending as of October 2026, declining as cases close at roughly 50 to 55 per month.
AstraZeneca's 2025 annual report states its PPI claims were resolved through settlements between 2022 and 2024, with few plaintiffs opting out; Takeda reached an agreement in principle in April 2024 and executed a final settlement in November 2024. These are company-specific settlements, not one global resolution — cases against remaining defendants and opt-out plaintiffs continue, and the docket will take years to clear.
The documented settlements so far
The largest documented resolution is the AstraZeneca settlement of October 2023: on October 3, 2023, Reuters reported AstraZeneca agreed to pay $425 million to resolve approximately 11,000 lawsuits alleging Nexium and Prilosec caused chronic kidney disease. The settlement covered prescription and lower-dose over-the-counter versions, and the company did not admit wrongdoing.
Across all manufacturers, total documented resolutions have reached roughly $590 million — a named aggregate of company settlements, not an estimate of what any individual received. Compensation varies widely by case, and most settlements are confidential. Individual outcomes depend on each person's medical evidence, as in the Pradaxa litigation, where Boehringer Ingelheim's $650 million settlement in 2014 resolved only claims with documented use and injury.
Key facts
- AstraZeneca agreed in October 2023 to pay $425 million to resolve roughly 11,000 lawsuits alleging Nexium and Prilosec caused chronic kidney disease, without admitting wrongdoing (Reuters, October 3, 2023).
- The federal litigation, MDL 2789, was centralized in 2017 in the District of New Jersey; about 11,404 cases remained pending as of October 2026, per the Judicial Panel on Multidistrict Litigation.
- Takeda reached an agreement in principle in April 2024 and executed a final settlement in November 2024 over Prevacid and Dexilant — a company-specific resolution, not a global one.
- A 2016 JAMA Internal Medicine study (Lazarus et al.) reported PPI users had roughly a 50 percent higher risk of developing chronic kidney disease than non-users.
- Total documented resolutions across all manufacturers have reached roughly $590 million in named company settlements.
Who qualifies and what evidence matters
New PPI kidney cases are rarely being accepted in 2026 — several firms have stopped taking new clients — but the qualifying criteria remain instructive. Lawyers looked for documented sustained PPI use (Nexium, Prilosec, Prevacid, Dexilant, or Protonix), a diagnosis of acute interstitial nephritis, acute kidney injury, or chronic kidney disease, and timing connecting the diagnosis to the period of use, with records ruling out the most obvious alternative causes.
The strongest files share a pattern: pharmacy or prescription records proving consistent use, lab work showing declining kidney function (rising creatinine, falling eGFR) during or shortly after use, and treating-physician notes that do not attribute the decline to diabetes or uncontrolled hypertension. Statutes of limitations in most states run from when you discovered, or should have discovered, the drug-injury link — waiting can close the door permanently.
This article is for general information only and is not legal, financial, or tax advice. Consult a qualified professional about your situation.
Who Benefits From This — and Who Does Not
This article is most useful if you took a proton pump inhibitor and later developed kidney problems, or if you are helping someone in that position. It explains the claim pattern, the science, and where the litigation stands — as general information, not medical or legal advice.
Who benefits
- People who took Nexium, Prilosec, Prevacid, or Protonix and later developed kidney injury: compare your drug, the dates you took it, and your kidney records with the pattern described here — acute interstitial nephritis, chronic kidney disease, or end-stage renal failure requiring dialysis or transplant.
- People tracking MDL 2789: about 11,404 cases were pending as of October 2026, closing at roughly 50 to 55 per month, and settlements are company-specific — AstraZeneca paid $425 million in October 2023 to resolve about 11,000 claims, and Takeda reached its final settlement in November 2024.
- Family members gathering records for a patient: prescription history, kidney test results, and dialysis or transplant records are the evidence that matters for both general and specific causation.
Who does not benefit
- People who took a PPI without any kidney injury: the claim pattern described here requires a documented kidney injury, so this article offers no claim path for them.
- People whose kidney disease has a documented unrelated cause: each case must still prove the PPI caused that person's injury, not merely that PPIs can cause kidney injury in general.
- Anyone expecting a fixed payout: outcomes vary widely by case, most settlements are confidential, and the roughly $590 million aggregate across manufacturers is not an amount any individual received.
the Camp Lejeune bladder-cancer claims, where tier and presumption rules decide who qualifies
FAQ
Are PPI kidney lawsuits still being filed in 2026?
Mostly, no. Several firms have stopped accepting new clients and the major company settlements are complete. About 11,400 existing cases remain pending in MDL 2789. If you believe you were injured and never filed, consult an attorney promptly about your state's statute of limitations.
Did the $425 million AstraZeneca settlement mean the company admitted fault?
No. AstraZeneca did not admit wrongdoing under the October 2023 settlement resolving roughly 11,000 Nexium and Prilosec claims. This is standard in large pharmaceutical settlements — the payment ends the litigation for covered claimants without a finding of liability.
What is the difference between the MDL and a class action?
In a class action, one case represents many people with a shared outcome. In an MDL, individual lawsuits are consolidated before one judge for pretrial proceedings but remain separate cases, each requiring its own proof of injury and causation.
Which PPI drugs were named in the lawsuits?
Nexium and Prilosec (AstraZeneca), Prevacid and Dexilant (Takeda), Protonix (Pfizer/Wyeth), and generics. Different manufacturers settled at different times, so your drug's maker determines which settlement, if any, covered your claim.
Who benefits most from reading about PPI kidney lawsuits — and who does not?
People who took a PPI such as Nexium or Prilosec and later developed kidney injury benefit most, because this article maps their drug, dates, and kidney records onto the failure-to-warn claim pattern and the current state of MDL 2789. It does not benefit people who took a PPI with no kidney injury, or anyone looking for a fixed payout figure — outcomes vary by case and most settlements are confidential.
How do I start if I think my kidney injury is linked to a PPI?
Start with the evidence checklist in this article: the PPI you took, the dates you took it, and your kidney diagnosis and treatment records. Then talk to your doctor about your kidney health and to a qualified attorney about whether your facts fit the claim pattern — and do not stop a prescribed medicine on the basis of an article alone.